Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 159

1.

BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.

Cremolini C, Di Bartolomeo M, Amatu A, Antoniotti C, Moretto R, Berenato R, Perrone F, Tamborini E, Aprile G, Lonardi S, Sartore-Bianchi A, Fontanini G, Milione M, Lauricella C, Siena S, Falcone A, de Braud F, Loupakis F, Pietrantonio F.

Ann Oncol. 2015 Jul 7. pii: mdv290. [Epub ahead of print]

PMID:
26153495
2.

Liver Resection for Advanced Intrahepatic Cholangiocarcinoma: A Cost-Utility Analysis.

Cillo U, Spolverato G, Vitale A, Ejaz A, Lonardi S, Cosgrove D, Pawlik TM.

World J Surg. 2015 Jul 7. [Epub ahead of print]

PMID:
26148521
3.

Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.

Toffoli G, Giodini L, Buonadonna A, Berretta M, De Paoli A, Scalone S, Miolo G, Mini E, Nobili S, Lonardi S, Pella N, Lo Re G, Montico M, Roncato R, Dreussi E, Gagno S, Cecchin E.

Int J Cancer. 2015 Jun 23. doi: 10.1002/ijc.29654. [Epub ahead of print]

PMID:
26099996
4.

De novo meta-assembly of ultra-deep sequencing data.

Mirebrahim H, Close TJ, Lonardi S.

Bioinformatics. 2015 Jun 15;31(12):i9-i16. doi: 10.1093/bioinformatics/btv226.

5.

BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.

Cigognetti M, Lonardi S, Fisogni S, Balzarini P, Pellegrini V, Tironi A, Bercich L, Bugatti M, Rossi G, Murer B, Barbareschi M, Giuliani S, Cavazza A, Marchetti G, Vermi W, Facchetti F.

Mod Pathol. 2015 May 29. doi: 10.1038/modpathol.2015.65. [Epub ahead of print]

PMID:
26022455
6.

When less is more: 'slicing' sequencing data improves read decoding accuracy and de novo assembly quality.

Lonardi S, Mirebrahim H, Wanamaker S, Alpert M, Ciardo G, Duma D, Close TJ.

Bioinformatics. 2015 May 20. pii: btv311. [Epub ahead of print]

PMID:
25995232
7.

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.

Schirripa M, Bergamo F, Cremolini C, Casagrande M, Lonardi S, Aprile G, Yang D, Marmorino F, Pasquini G, Sensi E, Lupi C, De Maglio G, Borrelli N, Pizzolitto S, Fasola G, Bertorelle R, Rugge M, Fontanini G, Zagonel V, Loupakis F, Falcone A.

Br J Cancer. 2015 Jun 9;112(12):1921-8. doi: 10.1038/bjc.2015.142. Epub 2015 May 5.

PMID:
25942399
8.

CLARK: fast and accurate classification of metagenomic and genomic sequences using discriminative k-mers.

Ounit R, Wanamaker S, Close TJ, Lonardi S.

BMC Genomics. 2015 Mar 25;16:236. doi: 10.1186/s12864-015-1419-2.

9.

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.

Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F; RAISE Study Investigators.

Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12.

PMID:
25877855
10.

Bevacizumab and first-line chemotherapy for older patients with advanced colorectal cancer: final results of a Community-based Observational Italian Study.

Lutrino SE, Bergamo F, Schirripa M, Rosati G, Avallone A, Giampieri R, Cordio S, Berretta M, Llimpe FR, Pisa FE, Lonardi S, Loupakis F, Fasola G, Aprile G.

Anticancer Res. 2015 Apr;35(4):2391-9.

PMID:
25862905
11.

Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis.

Terrazzino S, Argyriou AA, Cargnin S, Antonacopoulou AG, Briani C, Bruna J, Velasco R, Alberti P, Campagnolo M, Lonardi S, Cortinovis D, Cazzaniga M, Santos C, Kalofonos HP, Canonico PL, Genazzani AA, Cavaletti G.

J Peripher Nerv Syst. 2015 Mar;20(1):15-23. doi: 10.1111/jns.12110.

PMID:
25858589
12.

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.

Cremolini C, Loupakis F, Antoniotti C, Lonardi S, Masi G, Salvatore L, Cortesi E, Tomasello G, Spadi R, Zaniboni A, Tonini G, Barone C, Vitello S, Longarini R, Bonetti A, D'Amico M, Di Donato S, Granetto C, Boni L, Falcone A.

Ann Oncol. 2015 Jun;26(6):1188-94. doi: 10.1093/annonc/mdv112. Epub 2015 Feb 23.

PMID:
25712456
13.

Generating and reversing chronic wounds in diabetic mice by manipulating wound redox parameters.

Dhall S, Do DC, Garcia M, Kim J, Mirebrahim SH, Lyubovitsky J, Lonardi S, Nothnagel EA, Schiller N, Martins-Green M.

J Diabetes Res. 2014;2014:562625. doi: 10.1155/2014/562625. Epub 2014 Dec 23.

14.

Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients.

Ruzzo A, Graziano F, Galli F, Giacomini E, Floriani I, Galli F, Rulli E, Lonardi S, Ronzoni M, Massidda B, Zagonel V, Pella N, Mucciarini C, Labianca R, Ionta MT, Veltri E, Sozzi P, Barni S, Ricci V, Foltran L, Nicolini M, Biondi E, Bramati A, Turci D, Lazzarelli S, Verusio C, Bergamo F, Sobrero A, Frontini L, Magnani M.

Sci Rep. 2014 Nov 5;4:6828. doi: 10.1038/srep06828.

15.

Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.

Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A.

N Engl J Med. 2014 Oct 23;371(17):1609-18. doi: 10.1056/NEJMoa1403108.

16.

MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin.

Cecchin E, Perrone G, Nobili S, Polesel J, De Mattia E, Zanusso C, Petreni P, Lonardi S, Pella N, D'Andrea M, Errante D, Rizzolio F, Mazzei T, Landini I, Mini E, Toffoli G.

Pharmacogenomics J. 2015 Jun;15(3):219-25. doi: 10.1038/tpj.2014.64. Epub 2014 Oct 21.

PMID:
25331073
17.

Characterization of the immune cell repertoire in the normal fallopian tube.

Ardighieri L, Lonardi S, Moratto D, Facchetti F, Shih IeM, Vermi W, Kurman RJ.

Int J Gynecol Pathol. 2014 Nov;33(6):581-91. doi: 10.1097/PGP.0000000000000095.

PMID:
25272297
18.

SDF-1 inhibition targets the bone marrow niche for cancer therapy.

Roccaro AM, Sacco A, Purschke WG, Moschetta M, Buchner K, Maasch C, Zboralski D, Zöllner S, Vonhoff S, Mishima Y, Maiso P, Reagan MR, Lonardi S, Ungari M, Facchetti F, Eulberg D, Kruschinski A, Vater A, Rossi G, Klussmann S, Ghobrial IM.

Cell Rep. 2014 Oct 9;9(1):118-28. doi: 10.1016/j.celrep.2014.08.042. Epub 2014 Sep 25.

19.

PuFFIN--a parameter-free method to build nucleosome maps from paired-end reads.

Polishko A, Bunnik EM, Le Roch KG, Lonardi S.

BMC Bioinformatics. 2014;15 Suppl 9:S11. doi: 10.1186/1471-2105-15-S9-S11. Epub 2014 Sep 10.

20.

Second-line chemotherapy in advanced biliary cancer: the present now will later be past.

Vivaldi C, Fornaro L, Cereda S, Aprile G, Santini D, Silvestris N, Lonardi S, Leone F, Milella M, Brandi G, Vasile E.

Ann Oncol. 2014 Dec;25(12):2443-4. doi: 10.1093/annonc/mdu379. Epub 2014 Aug 13. No abstract available.

PMID:
25122694
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk